Nationwide Children's Hospital (NCH)

Nationwide Children's Hospital (NCH)

Nationwide Children's Hospital began in 1892 as a nine-bed children's clinic and grew into one of America's largest pediatric academic medical centers. CEO Timothy Robinson and Board Chair Abigail Wexner oversee an institution whose asset base fuses clinical operations, a major philanthropic partnership with the Nationwide Foundation, and a real estate portfolio concentrated in Columbus's Southern Orchards and Linden neighborhoods. The hospital also anchors the Ohio State University Department of Pediatrics, embedding its clinical mission within the largest university in the state. NCH deploys capital across direct life sciences commercialization, real estate, and a dedicated venture fund. The Abigail Wexner Research Institute houses over 900 researchers and more than $200 million in annual research funding, generating the intellectual property feeding the hospital's investment pipeline. Its co-investment vehicle with Rev1 Ventures — the Rev1 Nationwide Children's Hospital Fund I — targets early-stage biotech and medtech startups spinning out of the research institute. On the manufacturing side, Andelyn Biosciences, a for-profit subsidiary, operates a commercial gene-therapy production facility in the Ohio State University Innovation District. The hospital's real estate holdings include its Main Campus, the Healthy Neighborhoods Healthy Families housing portfolio, and the Eastland Plaza Pediatric Care Center. Philanthropic inflows provide a structural advantage. The Nationwide Foundation committed $100 million over ten years in 2024, building on a naming-rights relationship that dates back to 2007. The Kids Mental Health Foundation and Nationwide Children's Hospital Foundation operate as parallel fundraising vehicles, while Children's Miracle Network Hospitals membership supplies additional national-level donor access. The hospital's professional footprint includes American Academy of Pediatrics leadership positions, though total staffing numbers covering investment personnel are not publicly disclosed. NCH's structural differentiator is its captive R&D-to-commercialization flywheel. Unlike most endowments that operate as arms-length allocators, the hospital directly controls the innovation pipeline — from federally funded pediatric research to venture-stage spinouts to industrial-scale gene-therapy manufacturing. This vertical integration collapses the typical distance between basic science and monetization, a posture that more closely resembles a corporate venture arm than a traditional non-profit asset owner.